制藥網(wǎng)>產(chǎn)品庫(kù)>原料藥中間體、制劑>生物試劑>其它試劑>>曲妥珠-單抗

曲妥珠-單抗

參考價(jià)	￥1600.00

參考價(jià)

￥1600.00

具體成交價(jià)以合同協(xié)議為準(zhǔn)

公司名稱(chēng)杭州昊鑫生物科技股份有限公司
品牌MCE
型號(hào)HY-P9907
所在地杭州市
廠(chǎng)商性質(zhì)代理商
更新時(shí)間2024/6/27 17:02:15
訪(fǎng)問(wèn)次數(shù)454

產(chǎn)品標(biāo)簽:

Trastuzumab

規(guī)格

1mg

1600.00元

10000 支可售

在線(xiàn)詢(xún)價(jià) 收藏產(chǎn)品查看電話(huà) 同類(lèi)產(chǎn)品

聯(lián)系我們時(shí)請(qǐng)說(shuō)明是制藥網(wǎng) 上看到的信息，謝謝!

索取相關(guān)資料

公司介紹主營(yíng)產(chǎn)品

杭州昊鑫生物科技股份有限公司成立于2009年初，是一家面向生命科學(xué)領(lǐng)域，從事科研機(jī)構(gòu)、高校、院所及生產(chǎn)企業(yè)所需科研試劑、耗材，儀器銷(xiāo)售和服務(wù)面向全國(guó)。

產(chǎn)品和服務(wù)涵蓋生命科學(xué)研究技術(shù)的諸多方面，提供覆蓋分子生物學(xué)、細(xì)胞生物學(xué)、植物學(xué)、生物化學(xué)、蛋白組學(xué)、免疫學(xué)等領(lǐng)域的實(shí)驗(yàn)產(chǎn)品以及生物技術(shù)服務(wù)等。目前一級(jí)代理品牌有：MCE（Medchemexpress）、Biochannel、AATbio、invivogen、Abnova、Atlas、Origene、Biovision、云克?。–loud-clone）、艾德萊(Aidlab)、Cayman、Jackson、Epigentek、Prospec、Sciencell、icellbioscience（賽百慷）、hkABCbio、chondrex、Mybiosource、Abbexa、Innovrsrch、HPI、Hitobiotec、Greerlabs，Ostex，4ADI，LDN等。

經(jīng)營(yíng)理念：以誠(chéng)信為本，保證產(chǎn)品質(zhì)量求生存，創(chuàng)造企業(yè)核心競(jìng)爭(zhēng)力求發(fā)展 , 堅(jiān)持用戶(hù)至上、服務(wù)至上的原則。

展開(kāi)顯示更多內(nèi)容

胎牛血清、MCE抑制劑激動(dòng)劑、RNA提取試劑盒、ELISA試劑盒、重組蛋白

產(chǎn)品簡(jiǎn)介在線(xiàn)詢(xún)價(jià)

CAS號(hào)	180288-69-1	產(chǎn)地	國(guó)產(chǎn)
規(guī)格	1mg	級(jí)別	化工級(jí)
證書(shū)	ISO系列證書(shū)

Trastuzumab 是一種人源化 IgG1 單克隆抗體，其以高親和力與 HER2 選擇性結(jié)合。Trastuzumab 可用于 HER2 陽(yáng)性轉(zhuǎn)移性乳腺癌和 HER2 陽(yáng)性胃癌的研究。

曲妥珠-單抗產(chǎn)品信息

Trastuzumab (Synonyms: 曲妥珠-單抗; Anti-Human HER2, Humanized Antibody)

生物活性

Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

IC₅₀ & Target^[1]

HER2

體外研究(In Vitro)

Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets^[1]. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity^[2]. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1^[3].

體內(nèi)研究(In Vivo)

Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone^[1]. Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice^[3].

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04158258	Hoffmann-La Roche\|Latin American Cooperative Oncology Group	Breast Cancer	February 21, 2020
NCT02774681	Northwestern University\|Pfizer\|National Cancer Institute (NCI)	Breast Carcinoma Metastatic in the Brain\|Estrogen Receptor Negative\|HER2+Neu Negative\|HER2+Neu Positive\|Progesterone Receptor Negative\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer	August 31, 2016	Phase 2
NCT03493854	Hoffmann-La Roche	Early Breast Cancer	June 14, 2018	Phase 3

分子量：145531.50

Formula：C₆₄₇₀H₁₀₀₁₂N₁₇₂₆O₂₀₁₃S₄₂

CAS 號(hào)：180288-69-1

中文名稱(chēng)：曲妥珠-單抗；曲妥-單抗；群司珠-單抗

儲(chǔ)存方式;Please store the product under the recommended conditions in the Certificate of Analysis.

參考文獻(xiàn)

[1]. Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70.
[2]. Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51.
[3]. Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72.

注：產(chǎn)品僅用于科研